L&T Finance to raise funds worth Rs. 150 crore
L&T Finance to raise funds worth Rs. 150 crore

L&T Finance to raise funds worth Rs. 150 crore

Geyatee Deshpande Article rating: 5.0

L&T Finance Holdings is set to raise funds approximately of Rs. 150 crore through Cumulative Compulsorily Redeemable Non-Convertible Preference Shares (CRPS).

Auto stocks not out of the woods yet
Auto stocks not out of the woods yet

Auto stocks not out of the woods yet

Geyatee Deshpande Article rating: 3.5

The recent announcements on corporate tax rate cut and GST cuts were not effective enough to boost the auto stocks. In fact, the auto stocks continue to decline as, currently, there isn’t any major initiative announced by the government, particularly for the auto sector.

Pharma stocks tumble amid drug quality concerns
Pharma stocks tumble amid drug quality concerns

Pharma stocks tumble amid drug quality concerns

Geyatee Deshpande Article rating: 3.3

As the market reversed its trend to downside, pharma and auto stocks led the losses in Friday’s trading session. While auto stocks fell amid concerns about sales growth, the pharma stocks had to face the brunt of drug quality, triggered by suspension of ranitidine hydrochloric drug.

Rupee continues to strengthen for second-straight session
Rupee continues to strengthen for second-straight session

Rupee continues to strengthen for second-straight session

Pratik Shastri Article rating: 5.0

The currency appreciation is positive for the overall sentiment of the markets. Strong currency and decline in crude oil prices will be key drivers for the markets going ahead.

Strides Pharma gets approval for Solifenacin SuccinateTablets
Strides Pharma gets approval for Solifenacin SuccinateTablets

Strides Pharma gets approval for Solifenacin SuccinateTablets

Pritam Bhawar Article rating: 3.5

The company informed on Friday that Stride Pharma Global Pte Limited, Singapore, has received approval from the United States Food and Drug Administration (USFDA) for manufacturing Solifenacin SuccinateTablets, 5 mg and 10 mg.

RSS
First25132514251525162518252025212522Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR